Expanded Access

At LimmaTech, we believe vaccines are a sustainable solution to combat antimicrobial resistance (AMR) and bacterial infections. Prevention is always better than treatment!

Our Mission:

We are committed to fighting AMR by rapidly developing lifesaving vaccines. Our development pipeline focuses on addressing the world’s most critical pathogens, and we aim to deliver safe and effective global health products within the next couple of years.

Commitment to Safety:

Our commitment to safety is paramount, and our work is dedicated to ensuring an optimal clinical trial development before our vaccines are available to patients.

Expanded Access Update:

At this time, the current stage and structure of our clinical programs do not support expanded access to our vaccines. However, as we continue to gather more safety and efficacy data, this may change. We appreciate your understanding and patience as we work toward bringing these innovative vaccines to market.

For updates on LimmaTech-sponsored clinical trials, please visit www.clinicaltrials.gov.